These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

835 related articles for article (PubMed ID: 10860194)

  • 41. A comparison between the effects of hydrophobic and hydrophilic statins on osteoclast function in vitro and ovariectomy-induced bone loss in vivo.
    Hughes A; Rogers MJ; Idris AI; Crockett JC
    Calcif Tissue Int; 2007 Nov; 81(5):403-13. PubMed ID: 17982704
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Direct effects of statins on the vascular wall.
    Corsini A; Pazzucconi F; Arnaboldi L; Pfister P; Fumagalli R; Paoletti R; Sirtori CR
    J Cardiovasc Pharmacol; 1998 May; 31(5):773-8. PubMed ID: 9593078
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228)on migration, proliferation and cholesterol synthesis in arterial myocytes.
    Corsini A; Arnaboldi L; Raiteri M; Quarato P; Faggiotto A; Paoletti R; Fumagalli R
    Pharmacol Res; 1996 Jan; 33(1):55-61. PubMed ID: 8817647
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction?
    Comparato C; Altana C; Bellosta S; Baetta R; Paoletti R; Corsini A
    Nutr Metab Cardiovasc Dis; 2001 Oct; 11(5):328-43. PubMed ID: 11887430
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes.
    Assmus B; Urbich C; Aicher A; Hofmann WK; Haendeler J; Rössig L; Spyridopoulos I; Zeiher AM; Dimmeler S
    Circ Res; 2003 May; 92(9):1049-55. PubMed ID: 12676819
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells.
    Sidaway JE; Davidson RG; McTaggart F; Orton TC; Scott RC; Smith GJ; Brunskill NJ
    J Am Soc Nephrol; 2004 Sep; 15(9):2258-65. PubMed ID: 15339975
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synthetic statins: more data on newer lipid-lowering agents.
    Wierzbicki AS
    Curr Med Res Opin; 2001; 17(1):74-7. PubMed ID: 11464449
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression.
    Kah J; Wüstenberg A; Keller AD; Sirma H; Montalbano R; Ocker M; Volz T; Dandri M; Tiegs G; Sass G
    Oncol Rep; 2012 Sep; 28(3):1077-83. PubMed ID: 22710979
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of HMG-CoA reductase inhibition on PDGF- and angiotensin II- mediated signal transduction: suppression of c-Jun and c-Fos in human smooth muscle cells in vitro.
    Kreuzer J; Watson L; Herdegen T; Loebe M; Wende P; Kübler K
    Eur J Med Res; 1999 Apr; 4(4):135-43. PubMed ID: 10205288
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The influence of statin medications on prostate-specific antigen levels.
    Hamilton RJ; Goldberg KC; Platz EA; Freedland SJ
    J Natl Cancer Inst; 2008 Nov; 100(21):1511-8. PubMed ID: 18957682
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells.
    Mulhaupt F; Matter CM; Kwak BR; Pelli G; Veillard NR; Burger F; Graber P; Lüscher TF; Mach F
    Cardiovasc Res; 2003 Sep; 59(3):755-66. PubMed ID: 14499877
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages.
    Bernini F; Didoni G; Bonfadini G; Bellosta S; Fumagalli R
    Atherosclerosis; 1993 Dec; 104(1-2):19-26. PubMed ID: 8141843
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Statins have other beneficial properties besides their cholesterol lowering effect].
    Eriksson M
    Lakartidningen; 1998 Aug; 95(35):3670-2. PubMed ID: 9748780
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacological control of the mevalonate pathway: effect on arterial smooth muscle cell proliferation.
    Raiteri M; Arnaboldi L; McGeady P; Gelb MH; Verri D; Tagliabue C; Quarato P; Ferraboschi P; Santaniello E; Paoletti R; Fumagalli R; Corsini A
    J Pharmacol Exp Ther; 1997 Jun; 281(3):1144-53. PubMed ID: 9190847
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Do structural differences in statins correlate with clinical efficacy?
    Arnaboldi L; Corsini A
    Curr Opin Lipidol; 2010 Aug; 21(4):298-304. PubMed ID: 20581679
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fluvastatin and lovastatin inhibit granulocyte macrophage-colony stimulating factor-stimulated human eosinophil adhesion to inter-cellular adhesion molecule-1 under flow conditions.
    Robinson AJ; Kashanin D; O'Dowd F; Fitzgerald K; Williams V; Walsh GM
    Clin Exp Allergy; 2009 Dec; 39(12):1866-74. PubMed ID: 19689459
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative neuroprotective profile of statins in quinolinic acid induced neurotoxicity in rats.
    Kalonia H; Kumar P; Kumar A
    Behav Brain Res; 2011 Jan; 216(1):220-8. PubMed ID: 20696189
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effects of different types of statins on proliferation and migration of HGF-induced Human Umbilical Vein Endothelial Cells (HUVECs).
    Burgazli KM; Bui KL; Mericliler M; Albayrak AT; Parahuleva M; Erdogan A
    Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2874-83. PubMed ID: 24254555
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of fluvastatin sodium on the smooth muscle cells in atherosclerotic plaques. In vivo study using low-density lipoprotein receptor deficient Watanabe heritable hyperlipidemic (WHHL) rabbits.
    Shiomi M; Ito T; Tsukada T; Shiraishi M; Yata T
    Arzneimittelforschung; 1998 Jun; 48(6):680-5. PubMed ID: 9689427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.